Vanda Pharmaceuticals has been granted a patent for using a melatonin agonist to treat circadian rhythm disorders, especially in light perception impaired patients. The patent includes a method for administering tasimelteon, considering the patient’s use of beta-adrenergic receptor antagonists. GlobalData’s report on Vanda Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Vanda Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Vanda Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Vanda Pharmaceuticals's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Use of melatonin agonist tasimelteon in treating circadian rhythms

Source: United States Patent and Trademark Office (USPTO). Credit: Vanda Pharmaceuticals Inc

A recently granted patent (Publication Number: US11850229B2) outlines a method for administering tasimelteon to patients, particularly those suffering from Non-24-Hour Sleep-Wake Disorder. The method involves determining if the patient is being treated with a beta-adrenergic receptor antagonist. If not, the patient is to be administered 20 mg of tasimelteon once daily before bedtime. However, if the patient is on beta-adrenergic receptor antagonist treatment, this must be discontinued before administering tasimelteon.

Furthermore, the patent specifies that the beta-adrenergic receptor antagonist can be selected from a group including alprenolol, altenolol, carvedilol, metoprolol, and propanolol. This targeted approach aims to optimize the effectiveness of tasimelteon in regulating the sleep-wake cycle in patients with Non-24-Hour Sleep-Wake Disorder. By tailoring the administration of tasimelteon based on the patient's existing treatment regimen, the method outlined in the patent seeks to enhance the therapeutic outcomes for individuals struggling with this circadian rhythm disorder.

To know more about GlobalData’s detailed insights on Vanda Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies